Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-730-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013-2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013-2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Objective of study:
- absorption
- distribution
- excretion
- Principles of method if other than guideline:
- Principle of test:
- Disposition of β-OTNE, was investigated following a single oral (20 mg/kg bw) dose of [14C]β-OTNE to male Fisher rats.
- Short description of test conditions:
Oral administration: Single radiolabeled oral doses were administered to male rats, by intra-gastric gavage, in a dose volume of 5 mL/kg bw via a syringe. Following administration, animals were returned to metabolism cages. Groups of 4 animals were sacrificed at 4, 8, 24 and 48 h following administration. A group of bile duct cannulated male rats were also given 20 mg/kg as above and sacrificed after 48 h following administration.
- Parameters analysed / observed:
Disposition of radioactivity at 4, 8, 24 or 48h following oral administration and 24, 48 or 96h after dermal application (tissues, organs, feces, urine, bile)
Blood or tissue concentration versus time profiles
Blood and tissue toxicokinetic parameters (T1/2, Mean Residence Time, AUC, Terminal elimination rate constant, Tmax, Cmax)
Excretion of radioactivity following administration - GLP compliance:
- not specified
- Radiolabelling:
- yes
- Remarks:
- [14C]β-OTNE
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms (Germantown, NY), Bile duct cannulated male Fisher rats were obtained from Hilltop Labs (Scottsdale, PA)
- Age at initiation: 8-12 weeks
- Housing: individual all glass metabolism cages
- Diet (e.g. ad libitum): Purina rodent chow (5002) ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 3 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.7–26.1
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.9%Saline:Alkamulus EL-620/L (9:1)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dose formulations contained [14C]β-OTNE (5 µCi/rat), an appropriate amount of non-radiolabeled OTNE in 0.9% saline:Alkamulus EL-620/L (9:1). Oral doses were administered by intra-gastric gavage in a dose volume of 5 mL/kg via a syringe equipped with a 16 gauge ball tipped gavage needle.
- Duration and frequency of treatment / exposure:
- Single doses were administered
- Dose / conc.:
- 20 mg/kg bw (total dose)
- No. of animals per sex per dose / concentration:
- 4 males per dose
- Control animals:
- no
- Details on study design:
- - Dose selection rationale: An oral dose of 20 mg/kg bw was selected based on the information available in the literature (ECHA registered substance database, 2013)
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, faeces, blood, cage washes, bile, skin (ears), dose site skin (dermal groups only), spleen, liver, kidney, brain, heart, lung, pancreas, thymus, testes, bladder, muscle (abdominal and hind leg), adipose (perirenal and epididymal), and stomach, cecum, large intestine, and small intestine (all with contents)
- Time and frequency of sampling: urine and feces were collected separately into flasks cooled over dry ice at 0–4, 4–8, 8–24, 24–48, 48–72, 72–96 h intervals. In the bile collection group, bile, urine and feces were collected separately into flasks cooled over dry ice at 0–4, 4–8, 8–24, and 24–48 h intervals. Blood was sampled at the end of the study. - Statistics:
- Non-compartmental analysis of blood or tissue concentration versus time data was conducted using Phoenix WinNonlin software, version 6.3 (Pharsight Corporation, Cary, NC). Individual animal data was modeled. Parameters estimated were: Lambda-z, rate constant of elimination; t1/2, half-life of elimination; Cmax, maximum concentration; Tmax, time at which the maximum concentration was achieved; AUC(0–t), area under the blood concentration versus time curve to last time point; AUC(0–1), area under the blood concentration versus time curve to infinity; AUC(0–1)/D, dose-adjusted area under the blood concentration versus time curve to infinity.
- Type:
- absorption
- Results:
- b-OTNE was well-absorbed after a single oral administration of 20 mg/kg bw [14C]β-OTNE in male rats. High fecal excretion was observed, due to excretion via bile. At least 86% of a 20 mg/kg bw oral dose was absorbed following administration.
- Type:
- distribution
- Results:
- Tissue/blood ratios (TBR) were highest in bladder (31±34), pancreas (11±4.6), liver (8.8±1.0), kidney (8.1±1.2), adipose (5.4±3.4), muscle (2±3.2) and spleen (2.6±1.2). AUC(0–48h) values were highest in the bladder, liver, kidney and pancreas.
- Type:
- excretion
- Results:
- 28% and 39% of the dose was recovered in urine and feces, respectively, and 73% of a 20 mg/kg bw dose was excreted in bile within 48 h post-administration.
- Details on absorption:
- Following oral administration of 20 mg/kg bw in male Fisher rats, [14C]β-OTNE was excreted mainly via urine and feces. The total dose excreted in urine 48 h post administration was 28% with the majority excreted within 24 h (25%) post-administration suggesting rapid urinary excretion of [14C]β-OTNE following oral administration. However, fecal excretion continued through 48 h post administration with 39% excreted by 48 h while the levels of radioactivity in the GI tract contents decreased slowly, suggesting a long residence time of OTNE in the gut. In bile duct cannulated rats, about 73% of a 20 mg/kg bw was eliminated in bile within 48 h post administration while the excretion in urine and feces decreased to 12.8% and 2.8%, respectively, from 29% and 39% observed for intact animals. These data supports that the high fecal excretion observed following oral administration was not due to poor absorption but excretion via bile; at least 86% (73%+12.8%) of a 20 mg/kg bw oral dose of [14C]β-OTNE was absorbed following administration in male rats. Additionally, about 80% of the dose excreted in bile was excreted within 4 h suggesting rapid absorption.
- Details on distribution in tissues:
- In tissues: The concentration of radioactive equivalents in tissues 4, 8, 24, and 48 h following oral administration in (excluding digestive tract tissues) reached a maximum at 8 h post dosing; tissue/blood ratios (TBR) were highest in bladder (31±34), pancreas (11±4.6), liver (8.8±1.0), kidney (8.1±1.2), adipose (5.4±3.4), muscle (2±3.2) and spleen (2.6±1.2). The overall half-life was 34.3 hours in blood and most tissues. AUC(0–48h) values were highest in the bladder, liver, kidney and pancreas.
- Details on excretion:
- Following an oral administration of 20 mg/kg bw in bile duct cannulated male rats, 73% of the dose was recovered in bile 48 h post dosing. The dose recovered in urine and feces 48 h post dosing was 12.8% and 2.8%, respectively.
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: Blood: 34h, Adipose Tissue: 30h, Bladder: 8.7h, Brain: 25h, Heart: 24h, Kidney: 25h, Liver: 35h, Lung: 27h, Muscle: 27h, Pancreas: 19h, Skin: 22h, Spleen: 17h, Testes: 20h, Thymus: 24h
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- Tmax: Blood: 20h, Adipose Tissue: 13h, Bladder: 14h, Brain: 19h, Heart: 17h, Kidney: 17h, Liver: 19h, Lung: 19h, Muscle: 15h, Pancreas: 16h, Skin: 16h, Spleen: 14h, Testes: 17h, Thymus: 17h
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: Blood: 26, Adipose Tissue: 71, Bladder: 521, Brain: 3.8, Heart: 19, Kidney: 182, Liver: 217, Lung: 25, Muscle: 34, Pancreas: 194, Skin: 17, Spleen: 45, Testes: 11, Thymus: 13
- Remarks:
- µg-eq.h/g
- Metabolites identified:
- yes
- Details on metabolites:
- It was deduced that the substance was conjugated based on the molecular weight.
- Conclusions:
- The data indicate that β-OTNE was well-absorbed following a single oral administration of 20 mg/kg bw [14C]β-OTNE in male rats. The reported oral absorption level of 86% is considered valid for use in further risk assessment for this substance and is based on radiolabel. the substance is fully metabolised and the key metabolite is the conjugated counterpart of OTNE. The DT50 is considered to be 34.3 hours also based on radiolabel.
- Executive summary:
Disposition of β-OTNE, was investigated following a single oral (20 mg/kg bw) dose of [14C] β-OTNE to male Fisher rats. The study was rated Klimisch 2, since the study was not conducted according to a guideline (not available), but the study design is documented well and the results are presented clearly. Single radiolabeled oral doses were administered to male rats, by intra-gastric gavage, in a dose volume of 5 mL/kg bw via a syringe. Following administration, animals were returned to metabolism cages. Groups of 4 animals were sacrificed at 4, 8, 24 and 48 h following administration. A group of bile duct cannulated male rats were also given 20 mg/kg bw as above and sacrificed after 48 h following administration.
Disposition of radioactivity was measured at 4, 8, 24 or 48h following oral administration (tissues, organs, feces, urine, bile). Blood and tissue toxicokinetic parameters (T1/2, Mean Residence Time, AUC, Terminal elimination rate constant, Tmax, Cmax) were determined, as well as excretion of radioactivity following administration. The data indicate that the substance was well-absorbed following a single oral administration of 20 mg/kg bw [14C] β-OTNE in male rats. At least 86% of a 20 mg/kg bw oral dose was absorbed. b-OTNE was distributed to tissues, with bladder, pancreas, liver, adipose, and kidney showing the highest exposure to the test substance. Excretion of the test substance was mainly via urine and feces following both routes of administration. Biliary excretion and enterohepatic recirculation contributed to the high and prolonged excretion in feces. The reported oral absorption level of 86%, is considered valid for use in further risk assessment for this substance. The substance is extensively metabolised because no beta-OTNE could be detected, the glucuronic conjugated is one of the key metabolites. The DT50 for OTNE based on radiolable is 34.3 hours: 1.43 days.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
- Principles of method if other than guideline:
- Principle of test method:
- Disposition of radioactivity was determined following a single application of 55 or 550 mg/kg bw [14C]β-OTNE to covered or uncovered dose sites in male Fisher rats.
- Short description of test conditions:
Dermal administration: Male rats were surgically fitted with indwelling jugular vein cannulae at the study laboratory. Single dermal doses of 55 or 550 mg/kg radiolabeled OTNE were applied to a 3x4 cm clipped area on the back of the animal in a dose volume of 1 mL/kg bw. Exposure was performed both with and without occlusion to protect from grooming. All animals were returned to metabolism cages following dosing. Groups of 4 animals were sacrificed at 24, 48, and 96 h following application.
- Parameters analysed / observed:
Disposition of radioactivity at 24, 48 or 96h after dermal application (tissues, organs, feces, urine, bile)
Blood or tissue concentration versus time profiles
Blood and tissue toxicokinetic parameters (T1/2, Mean Residence Time, AUC, Terminal elimination rate constant, Tmax, Cmax)
Excretion of radioactivity following administration - GLP compliance:
- not specified
Test material
- Reference substance name:
- Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- EC Number:
- 915-730-3
- Molecular formula:
- C16H26O
- IUPAC Name:
- Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- Reference substance name:
- 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- EC Number:
- 259-174-3
- EC Name:
- 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- Cas Number:
- 54464-57-2
- Molecular formula:
- C16H26O
- IUPAC Name:
- 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone
- Reference substance name:
- 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- EC Number:
- 268-978-3
- EC Name:
- 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- Cas Number:
- 68155-66-8
- Molecular formula:
- C16H26O
- IUPAC Name:
- 1-(2,3,8,8-tetramethyl-1,2,3,5,6,7,8,8a-octahydronaphthalen-2-yl)ethanone
- Reference substance name:
- 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- EC Number:
- 268-979-9
- EC Name:
- 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one
- Cas Number:
- 68155-67-9
- Molecular formula:
- C16H26O
- IUPAC Name:
- 1-(2,3,8,8-tetramethyl-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)ethanone
- Test material form:
- liquid
1
Constituent 1
Constituent 2
Constituent 3
- Radiolabelling:
- yes
- Remarks:
- [14C]β-OTNE
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms (Germantown, NY), Bile duct cannulated male Fisher rats were obtained
from Hilltop Labs (Scottsdale, PA)
- Age at initiation: 8-12 weeks
- Housing: individual all glass metabolism cages
- Diet (e.g. ad libitum): Purina rodent chow (5002) ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 3 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.7–26.1
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Type of coverage:
- other: open or site protected from ingestion (semi-occlusive)
- Vehicle:
- ethanol
- Duration of exposure:
- PREPARATION OF DOSING SOLUTIONS:
dose formulations contained [14C]β-OTNE (10 µCi/rat) and an appropriate amount of non-radiolabeled OTNE in ethanol in a dose volume of 1 mL/kg bw. - Doses:
- - Nominal doses: 55 mg/kg bw and 550 mg/kg/bw
- Dose volume: 1 mL/kg bw
- Rationale for dose selection: dermal doses selected were approximately 0.01 and 0.1% of LD50 values reported in rodents - No. of animals per group:
- 4 animals per dose
- Control animals:
- no
- Details on study design:
- DOSE PREPARATION
- Method for preparation of dose suspensions: dose formulations were prepared to contain [14C]β-OTNE (10 µCi/rat) and an appropriate amount of nonradiolabeled OTNE in ethanol in a dose volume of 1 mL/kg, method was not further specified.
TEST SITE
- Preparation of test site: on the day of dosing, the fur was clipped from the animal’s back and the clipped area on each animal was examined for nicks.
- Area of exposure: the outline of the dosing area of a 3 x 4 cm was inscribed on the back of the animal with a marker and defined as the dose area.
- Type of cover / wrap if used: a protective foam appliance with a non-occlusive cotton cloth cover and an aluminum grate
- Other: single dermal doses of 55 or 550 mg/kg bw were applied to the marked area using a syringe fitted with an 18-gauge gavage needle and spread evenly on the marked dose site; dose formulations contained [14C]β-OTNE (10 µCi/ rat) and an appropriate amount of non-radiolabeled OTNE in ethanol in a dose volume of 1 mL/kg bw. All animals were returned to metabolism cages following dosing. Groups of 4 animals were sacrificed at 24, 48, and 96 h following application.
SITE PROTECTION / USE OF RESTRAINERS FOR PREVENTING INGESTION: yes: In groups protected from oral grooming, prior to dosing animals, a protective foam appliance was glued onto each rat’s back using tape and medical adhesive (3M, St. Paul, MN). Following application of the dose, a non-occlusive cotton cloth cover was fitted over the appliance and an aluminum grate was placed over the entire appliance to secure the appliance to the rat and to protect the appliance from being chewed.
REMOVAL OF TEST SUBSTANCE
- Removal of protecting device: prior to blood collection, the protective appliance was removed.
- Washing procedures and type of cleansing agent: the dose site skin was washed with 8 gauzes moistened with soapy water, and 4 moistened with water, and rinsates and gauzes were collected.
- Time after start of exposure: 96 h
SAMPLE COLLECTION
- Collection of blood: at 6, 12, 24, 48, 72, or 96 h
- Collection of urine and faeces: 0–4, 4–8, 8–24 h in main study rats, 24–48, 48–72, 72–96 h in the bile collection group, bile, urine and feces were collected separately at 0–4, 4–8, 8–24, and 24–48 h intervals.
- Terminal procedure: at the end of all studies (except the bile duct cannulated group), the animals were euthanized by asphyxiation with CO2 and blood was collected via cardiac puncture into a heparinized syringe.
- Analysis of organs/tissues: skin (ears), dose site skin (dermal groups only), spleen, liver, kidney, brain, heart, lung, pancreas, thymus, testes, bladder, muscle (abdominal and hind leg), adipose (perirenal and epididymal), and stomach, cecum, large intestine, and small intestine (all with contents)
SAMPLE PREPARATION
- Storage procedure: urine and feces were collected separately into flasks cooled over dry ice, in the bile collection group, bile, urine and feces were collected separately into flasks cooled over dry ice. All samples collected were stored at -20°C until analyzed.
- preparation: Blood and tissues from all studies were aliquoted in triplicate. All tissues were minced before sampling ca. 100 mg aliquots for further processing. Tissues, skin, and carcass were digested in 2N ethanolic NaOH prior to analysis. Darker samples such as feces, blood, kidney, spleen, heart, and lungs were bleached. Duplicate aliquots of urine, and triplicate aliquots of cage rinse, feces, skin wash, blood, and tissue and carcass digests were added directly to vials containing Ultima Gold scintillation cocktail and analyzed for radioactivity content by liquid scintillation spectroscopy (LSS) using a Packard 1900CA Tri-Carb Liquid Scintillation Analyzer (Perkin Elmer, Waltham, MA).
ANALYSIS
- Method type(s) for identification: liquid scintillation counting
Results and discussion
- Signs and symptoms of toxicity:
- no effects
- Dermal irritation:
- not specified
- Absorption in different matrices:
- In general, the concentration of radioactive equivalents in tissues (excluding digestive tract tissues) reached a maximum by 24–48 h and declined by 96 h post dosing.
The concentrations were highest in kidney, adipose, pancreas, liver, bladder, and non-dose site skin. The percent dose recovered in tissues 96 h post application to the covered dose site was 0.37% and 0.60% for 55 and 550 mg/kg bw, respectively. Compared to animals with covered dose sites, the percent dose in tissues was increased slightly in groups with uncovered dose sites with 0.57% and 1% of the applied dose recovered at 96 h post application. For further details please refer to the tables in the "other information on results" section. - Total recovery:
- - Total recovery (% dose recovered at 96 h):
Uncovered 55 mg/kg bw: 34 +/- 2.8%
Uncovered 550 mg/kg bw: 80 +/- 7.4%
Covered 55 mg/kg bw: 74 +/- 2.8%
Covered 550 mg/kg bw: 90 +/-1.6%
Percutaneous absorptionopen allclose all
- Time point:
- 96 h
- Dose:
- 55 mg/kg bw (covered)
- Parameter:
- percentage
- Absorption:
- 14 %
- Key result
- Time point:
- 96 h
- Dose:
- 550 mg/kg bw (covered)
- Parameter:
- percentage
- Absorption:
- 15 %
- Time point:
- 96 h
- Dose:
- 55 mg/kg bw (uncovered)
- Parameter:
- percentage
- Absorption:
- 33 %
- Remarks on result:
- other: significant absorption due to oral grooming
- Time point:
- 96 h
- Dose:
- 550 mg/kg bw (uncovered)
- Parameter:
- percentage
- Absorption:
- 72 %
- Remarks on result:
- other: significant absorption due to oral grooming
Any other information on results incl. tables
Table 1. Disposition of radioactivity following a single dermal application of 55 or 550 mg/kg bw [14C]b-OTNE to male Fisher rats and sacrificed 24, 48 or 96 h following application.
Covered |
Uncovered |
|||||||||||
55 mg/kg |
550 mg/kg |
55 mg/kg |
550 mg/kg |
|||||||||
Sample |
24 h |
48 h |
96 h |
24 h |
48 h |
96 h |
24 h |
48 h |
96 h |
24 h |
48 h |
96 h |
Unabsorbed dose |
60±4.2 |
57±6.8 |
58±2.8 |
61±3.7 |
60±4.5 |
59±3.9 |
5.3±1.8 |
1.6±0.7 |
0.5±0.2 |
20±7.3 |
4.6±2.1 |
0.9±1.0 |
Dose site skin |
9.2±1.6 |
4.4±1.10 |
3.1±0.22 |
18±4.6 |
16±2.0 |
11±2.8 |
8.2±3.1 |
2.5±0.79 |
0.72±0.31 |
8.6±3.9 |
2.6±1.2 |
1.4±0.54 |
Absorbed dose |
8.9±1.0 |
13±1.5 |
14±1.9 |
10±1.1 |
14±1.2 |
15±9.9 |
36±12.2 |
35±6.0 |
33±2.4 |
54±12.3 |
68±6.1 |
72±6.9 |
Urineb |
1.2±0.3 |
3.0±0.6 |
5.1±0.6 |
0.9±0.2 |
3.9±0.4 |
8.1±1.2 |
6.3±2.6 |
11±1.8 |
14±1.2 |
9.5±2.8 |
29±3.7 |
36±3.6 |
Feces |
0.6±0.3 |
2.0±0.4 |
4.0±0.3 |
0.2±0.1 |
1.4±0.7 |
5.3±0.3 |
2.9±1.6 |
7.4±1.4 |
12±2.6 |
1.9±0.9 |
11±2.8 |
22±5.9 |
Tissues |
0.6±0.1 |
0.8±0.5 |
0.4±0.1 |
0.6±0.1 |
0.8±0.2 |
0.6±0.2 |
1.6±0.5 |
1.1±0.3 |
0.6±0.2 |
1.9±0.3 |
1.9±0.4 |
1.0±0.2 |
GI tractc |
4.3±0.7 |
4.3±0.7 |
3.1±0.6 |
2.7±0.2 |
3.5±0.4 |
2.5±0.8 |
16±4.0 |
12±2.2 |
4.6±0.2 |
9.9±2.5 |
8.3±0.9 |
5.1±0.8 |
Carcass |
2.3±0.1 |
2.5±0.9 |
1.7±0.5 |
5.8±1.2 |
4.1±1.3 |
2.9±1.2 |
10±4.0 |
3.9±0.6 |
1.5±0.2 |
31±8.6 |
18±1.4 |
7.3±3.3 |
Total |
78±6.2 |
74±9.0 |
74±2.8 |
89±2.1 |
91±2.1 |
90±1.6 |
50±11 |
39±4.9 |
34±2.8 |
84±2.0 |
80±3.2 |
80±7.4 |
Table 2. Tissue distribution of radioactivity following a single dermal application of 55 and 550 mg/kg bw [14C]b-OTNE to covered dose sites in male Fisher rats and sacrificed 24, 48 or 96 h following application.
Concentration (ng Equivalents/g Tissue) |
||||||
55 mg/kg |
550 mg/kg |
|||||
Tissue |
24 h |
48 h |
96 h |
24 h |
48 h |
96 h |
Blood |
246±113 |
258±68 |
191±23 |
2924±1367 |
5374±1689 |
2349±1618 |
Adipose |
1842±924 |
1472±555 |
963±623 |
21599±3881 |
25116±5679 |
19875±8054 |
Muscle |
208±90 |
657±817 |
188±134 |
1984±532 |
4335±2491 |
2883±1806 |
Skin |
4217±1536 |
3127±684 |
2405±1185 |
23017±5333 |
28747±6047 |
27947±9663 |
Bladder |
3477±3308 |
2403±1332 |
2104±1370 |
8466±2739 |
23919±16051 |
10225±3396 |
Testes |
200±81 |
136±32 |
92±14 |
1862±419 |
2084±512 |
1592±492 |
Kidney |
2697±434 |
1533±279 |
1132±229 |
32238±2309 |
28923±7053 |
18418±1999 |
Spleen |
360±100 |
508±377 |
440±262 |
3595±1531 |
4404±2247 |
3451±1921 |
Liver |
1818±262 |
1874±426 |
1747±250 |
14889±3572 |
19002±4625 |
15296±2055 |
Lung |
638±121 |
465±96 |
347±75 |
6068±956 |
6635±1296 |
4896±1561 |
Heart |
356±75 |
283±76 |
247±70 |
3734±484 |
4178±1093 |
3049±902 |
Brain |
128±28 |
82±18 |
63±13 |
1771±122 |
1717±450 |
1242±316 |
Thymus |
294±115 |
312±84 |
219±45 |
9031±564 |
9675±2885 |
4963±1043 |
Pancreas |
1816±708 |
2568±1775 |
1046±370 |
21942±3681 |
18080±2458 |
17389±12555 |
% Dose in Tissues |
0.56±0.14 |
0.76±0.50 |
0.37±0.14 |
0.55±0.09 |
0.83±0.16 |
0.60±0.24 |
Table 3. Tissue distribution of radioactivity in male Fisher rats following a single dermal application of 55 and 550 mg/kg bw [14C]b-OTNE to uncovered dose sites and sacrificed 24, 48 or 96 h following application.
Concentration (ng Equivalents/g Tissue) |
||||||
55 mg/kg |
550 mg/kg |
|||||
Tissue |
24 h |
48 h |
96 h |
24 h |
48 h |
96 h |
Blood |
1021±468 |
739±70 |
424±58 |
10950±2092 |
11546±2226 |
7483±1009 |
Adipose |
3803±1468 |
1660±307 |
784±408 |
39493±4907 |
57538±12802 |
29037±8190 |
Muscle |
621±305 |
555±438 |
360±175 |
10441±240 |
7477±3033 |
3605±707 |
Skin |
25997±11358 |
4270±477 |
1729±155 |
311904±21496 |
352727±76805 |
100693±38394 |
Bladder |
6080±230 |
3990±1738 |
1515±880 |
64338±21769 |
50426±57568 |
25114±26261 |
Testes |
472±164 |
303±29 |
129±14 |
7987±1323 |
5333±598 |
2608±759 |
Kidney |
7443±2449 |
3136±740 |
1385±129 |
103291±44534 |
65017±3982 |
32110±6845 |
Spleen |
1407±722 |
777±363 |
384±28 |
19961±15094 |
9629±1536 |
6039±787 |
Liver |
5910±1916 |
4909±1111 |
2730±97 |
44378±6188 |
48522±3416 |
36618±6926 |
Lung |
1747±580 |
595±160 |
460±59 |
19758±2021 |
15843±1749 |
8381±2615 |
Heart |
911±289 |
665±115 |
345±47 |
14112±4469 |
9640±1048 |
6168±2034 |
Brain |
324±105 |
149±17 |
89±6 |
4827±216 |
3306±453 |
1418±513 |
Thymus |
958±354 |
535±70 |
342±107 |
27550±8948 |
18755±5995 |
6146±2715 |
Pancreas |
5076±3388 |
1863±1054 |
833±158 |
33364±3211 |
34451±5020 |
12218±3613 |
% Dose in Tissues |
1.62±0.50 |
1.05±0.31 |
0.57±0.19 |
1.90±0.35 |
1.95±0.35 |
1.00±0.17 |
Effects of grooming and volatilisation
The absorption of b-OTNE was low and was not dose-dependent (14% and 15%, for 55 and 550 mg/kg, respectively). When the dose site was uncovered, the total dose absorbed increased suggesting significant oral grooming (33% and 72%, for 55 and 550 mg/kg, respectively). In addition, the total dose recovered was lower when the dose site was uncovered compared to covered dose sites suggesting rapid volatilization of the dose from the uncovered site.
Excretion after dermal absorption
Excretion following dermal dosing was mainly via urine and feces. The dose excreted in urine 96 h post application for 55 and 550 mg/kg bw, respectively, was ca. 5% and 8% in covered groups and ca.14% and 36% in the uncovered groups. The dose excreted in feces 96 h post application was slightly lower than in urine and was ca. 4% and ca. 5% in covered groups and ca. 12% and ca. 22% in the uncovered groups, for 55 and 550 mg/kg bw, respectively.
Applicant's summary and conclusion
- Conclusions:
- The percutaneous absorption of OTNE (using radiolabel) was determined to be 14% and 15% after semi-occlusive dermal application of 55 and 550 mg/kg bw, respectively. The reported percutaneous absorption level of 15% is the most conservative value and can be used for risk assessment purposes. The DT50 in at the low and high dose is 70 and 40 hours, respectively.
- Executive summary:
Disposition of β-OTNE was investigated following a single dermal (55 or 550 mg/kg) dose of [14C] β-OTNE to male Fisher rats. The study was rated Klimisch 2, since the study was not conducted according to a guideline (not available), but the study design is documented well and the results are presented clearly. Prior to inclusion in the study, male rats were surgically fitted with indwelling jugular vein cannulae at the study laboratory. On the day of dosing, the fur was clipped from the animal’s back and the clipped area on each animal was examined for nicks. The outline of the dosing area of a 3 x 4 cm was inscribed on the back of the animal with a marker and defined as the dose area. Single dermal doses of 55 or 550 mg/kg bw were applied to the marked area in a dose volume of 1 mL/kg. In groups protected from oral grooming, prior to dosing animals, a protective foam appliance was glued onto each rat’s back using tape and medical adhesive. Following application of the dose, a non-occlusive cotton cloth cover was fitted over the appliance and an aluminium grate was placed over the entire appliance to secure the appliance to the rat and to protect the appliance from being chewed. All animals were returned to metabolism cages following dosing. Groups of 4 animals were sacrificed at 24, 48, and 96 h following application. The absorption of β-OTNE was low and was not dose-dependent (14% and 15%, for 55 and 550 mg/kg, respectively). When the dose site was uncovered, the total dose absorbed increased suggesting significant oral grooming (33% and 72%, for 55 and 550 mg/kg bw, respectively). In addition, the total dose recovered was lower when the dose site was uncovered compared to covered dose sites suggesting rapid volatilization of the dose from the uncovered site. b-OTNE was distributed to tissues with bladder, pancreas, liver, adipose, and kidney showing the highest exposure to the test substance. Excretion of the substance was mainly via urine and faeces following both routes of administration. The dose excreted in urine 96 h post application for 55 and 550 mg/kg bw, respectively, was ca. 5% and 8% in covered groups and ca.14% and 36% in the uncovered groups. The dose excreted in faeces 96 h post application was slightly lower than in urine and was ca. 4% and ca. 5% in covered groups and ca. 12% and ca. 22% in the uncovered groups, for 55 and 550 mg/kg bw, respectively. Biliary excretion and enterohepatic recirculation contributed to the high and prolonged excretion of the test substance in faeces. The higher fecal and urinary excretion levels in the uncovered group are also suggesting a significant effect of oral intake due to grooming. The results for this study indicate that a covered dermal exposure provides a reliable estimate of the percutaneous absorption of the test substance, as it prevents oral intake due to grooming, and rapid volatilisation of the substance. The reported percutaneous absorption level of 15% is the most conservative value and can be used for risk assessment purposes. The The DT50 in at the low and high dose is 70 and 40 hours, respectively.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)